Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H6-MSA is a recombinant, hexahistidine-tagged version of murine serum albumin (MSA) expressed in the yeast *Pichia pastoris*. Developed by researchers at McMaster University and Canadian Blood Services, it serves as a pharmacokinetic control protein in studies investigating extended half-life (EHL) strategies for Hereditary Angioedema (HAE) treatments. The protein leverages the neonatal Fc receptor (FcRn) recycling pathway to maintain a prolonged circulatory residency time, exhibiting a terminal half-life of approximately 21.4 hours in murine models. Its primary utility is as a benchmark for evaluating the efficacy of albumin-fusion platforms, such as those involving truncated C1 esterase inhibitor (C1INH) variants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H6-MSA.